FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2516045111> ?p ?o ?g. }

• W2516045111 endingPage "736" @default.
• W2516045111 startingPage "736" @default.
• W2516045111 abstract "Abstract Introduction: The Orphan Drug Act (ODA) of 1983 established incentives for the development of drugs that treat rare or orphan diseases. The ODA targets therapies for diseases affecting fewer than 200,000 patients in the US. As a consequence, orphan drug development was stimulated and therapies have been developed to treat a variety of previously underserved conditions including acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, myelodysplastic syndromes, Gaucher disease and Hunter syndrome. Between 1973 to 1983, prior to the ODA, less than 10 drugs for orphan conditions were available to patients, while in 2013 the FDA website listed more than 400 approved orphan drugs (this includes both new molecular entities and supplemental applications/indications). Due to the perceived high therapy costs and therefore potential impact on payer's drug budgets, orphan drugs are facing increasing scrutiny from payers. The objective of this study was to estimate the total annual expenditures on orphan drugs in the US from 2007 to 2013, and to evaluate orphan drug expenditures as a percentage of total pharmaceutical expenditures. Methods: A list of drugs which have been approved by the FDA and given orphan status in the US since the establishment of the ODA through the end of 2013 was generated from the US FDA Orphan Drug Product designation website (N=366 unique products). Only branded products (N=357) were considered in this analysis. The IMS MIDAS database, the gold standard for audited biopharmaceutical sales, was used to assess orphan drug and total drug expenditures. The MIDAS database integrates and extends the IMS National Prescription Audits, which detail estimated sales by product and therapy class through retail and non-retail channels at the unit of the product pack level. The analysis focused on orphan drugs with expenditures measured between 2007 and 2013 in the MIDAS database. Only products with a single orphan indication or with multiple indications which were all orphan were included in the analysis (N=303). Total orphan drug expenditures were calculated annually from 2007 to 2013 and further reported as a proportion of total annual pharmaceutical drug expenditures. All expenditures were adjusted to 2014 USD using the Bureau of Economic Analysis GDP deflator. Expenditures for orphan drugs with cancer indications were evaluated as a subset of all orphan drugs. Results: Between 2007 and 2013, expenditures were measured for a final N=266 branded orphan drugs in the MIDAS database; 37 out of 303 were either not present or had no sales in MIDAS. Orphan drug expenditures totaled $15.0 billion (B) in 2007 and $25.6B in 2013, representing 4.8% to 7.6% of total U.S. pharmaceutical drug expenditures in 2007 and 2013, respectively (Figure 1). There were 74 (27.8%) orphan drugs identified with an orphan cancer indication with expenditures representing 26.7% (2007) and 34.8% (2013) of total orphan drug expenditures. Over the same period (2007–2013), a total of 145 orphan drugs were granted approval (both new molecular entities and supplemental applications/indications). Conclusions: Although the ODA has led to an increase in the number of approved orphan drugs and the annual expenditures on orphan drugs, the overall budget impact of orphan drugs is relatively small and has remained fairly stable as a proportion of total pharmaceutical expenditures. Concerns that growth in orphan drug expenditures may lead to unsustainable drug expenditures do not appear to be justified. Figure 1 Proportion of Total US Drug Expenditures, 2007-2013: Orphan and Non-Orphan Drugs Figure 1. Proportion of Total US Drug Expenditures, 2007-2013: Orphan and Non-Orphan Drugs Disclosures Divino: IMS Health: Employment. Dekoven:IMS Health: Employment. Wang:MKTXS: Employment. Kleinrock:IMS Health: Employment. Harvey:Celgene, Millennium, Onyx and Novartis: Research Funding. Wade:IMS Health: Employment. Kaura:Celgene: Employment, Equity Ownership." @default.
• W2516045111 created "2016-09-16" @default.
• W2516045111 creator A5011077808 @default.
• W2516045111 creator A5043235685 @default.
• W2516045111 creator A5044626278 @default.
• W2516045111 creator A5050619579 @default.
• W2516045111 creator A5054726198 @default.
• W2516045111 creator A5055552324 @default.
• W2516045111 creator A5065999728 @default.
• W2516045111 date "2014-12-06" @default.
• W2516045111 modified "2023-09-27" @default.
• W2516045111 title "The Budget Impact of Orphan Drugs in the U.S.: A 2007-2013 MIDAS Sales Data Analysis" @default.
• W2516045111 doi "https://doi.org/10.1182/blood.v124.21.736.736" @default.
• W2516045111 hasPublicationYear "2014" @default.
• W2516045111 type Work @default.
• W2516045111 sameAs 2516045111 @default.
• W2516045111 citedByCount "1" @default.
• W2516045111 countsByYear W25160451112019 @default.
• W2516045111 crossrefType "journal-article" @default.
• W2516045111 hasAuthorship W2516045111A5011077808 @default.
• W2516045111 hasAuthorship W2516045111A5043235685 @default.
• W2516045111 hasAuthorship W2516045111A5044626278 @default.
• W2516045111 hasAuthorship W2516045111A5050619579 @default.
• W2516045111 hasAuthorship W2516045111A5054726198 @default.
• W2516045111 hasAuthorship W2516045111A5055552324 @default.
• W2516045111 hasAuthorship W2516045111A5065999728 @default.
• W2516045111 hasBestOaLocation W25160451111 @default.
• W2516045111 hasConcept C150903083 @default.
• W2516045111 hasConcept C2777494893 @default.
• W2516045111 hasConcept C2780035454 @default.
• W2516045111 hasConcept C2781047461 @default.
• W2516045111 hasConcept C60644358 @default.
• W2516045111 hasConcept C71924100 @default.
• W2516045111 hasConcept C75480439 @default.
• W2516045111 hasConcept C86803240 @default.
• W2516045111 hasConcept C98274493 @default.
• W2516045111 hasConceptScore W2516045111C150903083 @default.
• W2516045111 hasConceptScore W2516045111C2777494893 @default.
• W2516045111 hasConceptScore W2516045111C2780035454 @default.
• W2516045111 hasConceptScore W2516045111C2781047461 @default.
• W2516045111 hasConceptScore W2516045111C60644358 @default.
• W2516045111 hasConceptScore W2516045111C71924100 @default.
• W2516045111 hasConceptScore W2516045111C75480439 @default.
• W2516045111 hasConceptScore W2516045111C86803240 @default.
• W2516045111 hasConceptScore W2516045111C98274493 @default.
• W2516045111 hasIssue "21" @default.
• W2516045111 hasLocation W25160451111 @default.
• W2516045111 hasOpenAccess W2516045111 @default.
• W2516045111 hasPrimaryLocation W25160451111 @default.
• W2516045111 hasRelatedWork W2086036313 @default.
• W2516045111 hasRelatedWork W2124466768 @default.
• W2516045111 hasRelatedWork W2184628870 @default.
• W2516045111 hasRelatedWork W2928903530 @default.
• W2516045111 hasRelatedWork W2943083791 @default.
• W2516045111 hasRelatedWork W3118624259 @default.
• W2516045111 hasRelatedWork W3178364451 @default.
• W2516045111 hasRelatedWork W4229892026 @default.
• W2516045111 hasRelatedWork W4234786210 @default.
• W2516045111 hasRelatedWork W4308043995 @default.
• W2516045111 hasVolume "124" @default.
• W2516045111 isParatext "false" @default.
• W2516045111 isRetracted "false" @default.
• W2516045111 magId "2516045111" @default.
• W2516045111 workType "article" @default.